The Marken Board of Directors is pleased to announce the appointment of Wesley P. Wheeler, MBA as Chief Executive Officer. Mr. Wheeler succeeds Gerard Barba, who willremain the Chairman of the Marken Board of Directors.
Marken’s Board and executive management team have sought to add an executive such as Mr. Wheeler for his in depth of experience in the life science industry as well as a strong background in logistics to further strengthen market leadership and maintain Marken’s growth path.
Prior to joining Marken, Wes held the title of President and CEO of Patheon Inc., a contract manufacturing services company. Wes was also a former President of Valeant Pharmaceuticals International, and has previously held senior executive roles of increasing responsibility in manufacturing, marketing and engineering at GlaxoSmithKline, plc. Preceding his 22 year career in pharmaceuticals, Mr. Wheeler had a successful 12 year career at ExxonMobil. He holds a bachelor’s degree in Mechanical Engineering and aMasters of Business Administration.
“As the nature of biopharmaceutical R&D changes, well controlled clinical supply chains will be a significant factor in the success of key life science companies and the industries that support them. The Board and I feel that Wes can bring his experience from the drug manufacturing, biotechnology, and traditional pharmaceutical industries to augment an already strong management team and continue Marken’s growth”, said Gerard Barba,Marken’s Chairman.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.